MARKET

APLT

APLT

Applied Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.140
-0.220
-16.18%
After Hours: 1.200 +0.06 +5.26% 19:18 08/09 EDT
OPEN
1.350
PREV CLOSE
1.360
HIGH
1.360
LOW
1.100
VOLUME
484.44K
TURNOVER
0
52 WEEK HIGH
19.14
52 WEEK LOW
0.7277
MARKET CAP
29.91M
P/E (TTM)
-0.2848
1D
5D
1M
3M
1Y
5Y
Applied Therapeutics to Sponsor and Present at the 2022 Galactosemia Foundation Conference
Gold sponsor of the 2022 Galactosemia Foundation Conference; new website and educational resources as part of ongoing commitment to the Galactosemia communityApplied Therapeutics to present research and clinical update NEW YORK, July 28, 2022 (GLOBE NEWSWI...
GlobeNewswire · 07/28 11:00
Nasdaq Jumps Over 100 Points; Applied Therapeutics Shares Plummet
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Thursday.
Benzinga · 06/23 19:13
Dow Jones Turns Lower; F-star Therapeutics Shares Spike Higher
U.S. stocks pared gains midway through trading, with the Dow Jones dropping 100 points on Thursday.
Benzinga · 06/23 16:31
44 Stocks Moving In Thursday's Mid-Day Session: F-star Therapeutics, Revlon And More
 Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering.
Benzinga · 06/23 16:29
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 06/23 14:31
F-star, Valneva top healthcare gainers; Applied Therapeutics, Mereo lead losers' pack
Gainers: F-star Therapeutics FSTX +57%. Valneva VALN +23%. Nutriband NTRB +16%. Rain Therapeutics (RAIN) +15%. uniQure (QURE) +15%. Losers: Applied Therapeutics APLT -25%. Mereo BioPharma Group (MREO) -14%. Rigel Pharmaceuticals (RIGL) -12%. bluebird bio (...
Seekingalpha · 06/23 14:04
Zai Lab, Xenon Pharmaceuticals among premarket losers' pack
Applied Therapeutics (APLT) -22% on <a href="https://seekingalpha.com/news/385...
Seekingalpha · 06/23 12:20
22 Stocks Moving in Thursday's Pre-Market Session
Gainers WISeKey International Holding AG (NASDAQ: WKEY) rose 74.4% to $2.32 in pre-market trading. WISeKey International recently issued 2022 first-half revenue guidance for its IoT segment.
Benzinga · 06/23 10:30
More
No Data
Learn about the latest financial forecast of APLT. Analyze the recent business situations of Applied Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
40.00%Buy
20.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average APLT stock price target is 13.38 with a high estimate of 29.00 and a low estimate of 2.500.
High29.00
Average13.38
Low2.500
Current 1.140
EPS
Actual
Estimate
-1.00-0.75-0.50-0.25
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 93
Institutional Holdings: 13.40M
% Owned: 51.09%
Shares Outstanding: 26.24M
TypeInstitutionsShares
Increased
19
2.85M
New
16
607.53K
Decreased
19
1.77M
Sold Out
13
4.25M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.83%
Pharmaceuticals & Medical Research
-0.22%
Key Executives
Chairman/President/Chief Executive Officer/Founder/Director
Shoshana Shendelman
Other
Adam Hansard
Other
Riccardo Perfetti
Lead Director/Independent Director
Teena Lerner
Independent Director
Leslie Funtleyder
Independent Director
Stacy Kanter
Independent Director
Joel Marcus
Independent Director
Jay Skyler
No Data
No Data
About APLT
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).

Webull offers kinds of Applied Therapeutics Inc stock information, including NASDAQ:APLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APLT stock methods without spending real money on the virtual paper trading platform.